Education
About Us
Working with TipRanks
Follow Us
PureTech Health PLC (GB:PRTC)
LSE:PRTC
PRTC Stock Chart & Stats
134.80p
0.20p(0.14%)
At close: 4:00 PM EST
134.80p
0.20p(0.14%)
Day’s Range― - ―
52-Week Range100.40p - 149.00p
Previous CloseN/A
Volume88.39K
Average Volume (3M)444.90K
Market Cap
£311.29M
Enterprise Value190.63M
Total Cash (Recent Filing)£321.55M
Total Debt (Recent Filing)£20.92M
Price to Earnings (P/E)9.0
Beta1.92
Next Earnings
Apr 23, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding241,684,040
10 Day Avg. Volume437,187
30 Day Avg. Volume444,904
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.22
Price to Sales (P/S)117.44
P/FCF Ratio-3.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£508.00Price Target Upside276.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity / RunwayNearly $320M in cash and short-term investments provides an operational runway into 2028, materially reducing near-term financing pressure. This durable liquidity supports continued R&D, clinical programs and spinouts, lowering dilution risk and enabling milestone-driven partnerships.
Value In Equity Stakes And SpinoutsA 35.1% stake in Seaport (post-money $733M) and proceeds from recent raises create durable upside optionality. Equity holdings and retained economic interests align PureTech with subsidiary value creation, enabling future monetization via exits, royalties or licensing that bolster long-term cash generation.
Operational Cost DisciplineOperating expenses fell materially year‑over‑year, indicating sustainable cost discipline. A structurally lower burn rate improves capital efficiency, extends runway for core programs and spinouts, and increases flexibility to allocate resources toward high‑value clinical milestones over the medium term.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow and historically inconsistent free cash flow mean PureTech depends on financing and investing activities to fund operations. Over 2–6 months this raises dilution and refinancing risk, potentially constraining trial progress and the company’s ability to self‑fund spinouts.
Volatile Profitability And MarginsDespite a net profit turn in 2024, negative EBIT/EBITDA margins and volatile revenue/net income trends indicate unstable underlying profitability. This undermines predictable internal funding for development, increases reliance on milestone/licensing receipts, and clouds sustainable commercial economics.
Leadership And Funding UncertaintyRecent interim CEO/Chair appointments combined with no confirmed timelines for external funding of Celea and Gallop create execution and governance uncertainty. Leadership transitions and unclear capital plans can delay program advancement, complicate partner engagement and elevate operational risk over the medium term.
PureTech Health News
PRTC FAQ
What was PureTech Health PLC’s price range in the past 12 months?
PureTech Health PLC lowest share price was 100.40p and its highest was 149.00p in the past 12 months.
What is PureTech Health PLC’s market cap?
PureTech Health PLC’s market cap is £311.29M.
When is PureTech Health PLC’s upcoming earnings report date?
PureTech Health PLC’s upcoming earnings report date is Apr 23, 2026 which is in 64 days.
How were PureTech Health PLC’s earnings last quarter?
PureTech Health PLC released its earnings results on Aug 28, 2025. The company reported -0.14p earnings per share for the quarter, beating the consensus estimate of -0.15p by 0.01p.
Is PureTech Health PLC overvalued?
According to Wall Street analysts PureTech Health PLC’s price is currently Undervalued.
Does PureTech Health PLC pay dividends?
PureTech Health PLC does not currently pay dividends.
What is PureTech Health PLC’s EPS estimate?
PureTech Health PLC’s EPS estimate is -0.14.
How many shares outstanding does PureTech Health PLC have?
PureTech Health PLC has 241,684,040 shares outstanding.
What happened to PureTech Health PLC’s price movement after its last earnings report?
PureTech Health PLC reported an EPS of -0.14p in its last earnings report, beating expectations of -0.15p. Following the earnings report the stock price went down -5.522%.
Which hedge fund is a major shareholder of PureTech Health PLC?
Currently, no hedge funds are holding shares in GB:PRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PureTech Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.20%
12-Months-Change
Fundamentals
Return on Equity
15.04%
Trailing 12-Months
Asset Growth
-12.00%
Trailing 12-Months
Company Description
PureTech Health PLC
PureTech Health (PRTC) is a biotechnology company focused on discovering, developing, and commercializing innovative therapies for serious diseases. The company operates primarily in the health and biotechnology sectors, leveraging its expertise in drug development to create a diverse pipeline of therapeutic candidates across various domains, including immunology, neurology, and oncology. PureTech also engages in collaborations and partnerships with other biotech and pharmaceutical companies to advance its proprietary technologies and products.
PRTC Stock 12 Month Forecast
Average Price Target
508.00p
▲(276.85% Upside)
Technical Analysis
Avacta Group plc
―
ImmuPharma
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―
Options Prices
Currently, No data available
---